Detailed Narrative
GLP-1 Market Expansion and Access
Eli Lilly is significantly expanding access to its GLP-1 medicines, particularly for obesity. The Medicare GLP-1 bridge program, launched July 1, grants 20 million eligible Americans insurance coverage for GLP-1s at a low out-of-pocket cost of $50 per month, increasing coverage by 35%. Foundayo has also received its first international approvals for obesity in the UAE, Saudi Arabia, and Mexico, with early uptake demonstrating pent-up demand. The company expects a global rollout in all major markets in 2027, with over 40 markets currently under regulatory review.
Pipeline Progress in Cardiometabolic Health
The company announced positive top-line results from three Phase III trials for Retatrutide (Triumph 1, 2, 3) in obesity, showing profound weight loss and improvements in A1c, cardiovascular risk factors, osteoarthritis pain, and sleep apnea. The U.S. submission for Retatrutide is planned for Q1 2027 under the BLA pathway. Orphaglipron's U.S. submission for type 2 diabetes is complete, with detailed results showing superior glycemic control and weight reduction against oral semaglutide. Additionally, a positive CHMP opinion was received for insulin epatoralpha in the EU for type 2 diabetes.
Neuroscience and Oncology Advancements
Lilly is expanding its presence in neuroscience through strategic acquisitions, including Beckley for treatment-resistant depression and Synteza for sleep-wake disorders. In oncology, Jaypirca continues strong growth with new Phase III data showing a 45% reduction in disease progression or death in CLL, and Selpercatinib demonstrated an 83% reduction in recurrence or death in adjuvant RET fusion-positive NSCLC. The company also highlighted promising early data from acquired hematology programs, AG111095 and KLN 1010.
Immunology and Infectious Disease Portfolio
In immunology, the FDA approved a new maintenance dosing regimen for Lebrikizumab, allowing for as few as six injections per year for atopic dermatitis, with pediatric indications submitted in the U.S. and planned globally. Lilly is also building a platform for infectious disease prevention through acquisitions of Kurbo (shingles vaccine), LimmaTech Biologics (bacterial infections), and Vaccine Company (Epstein-Barr virus), aiming to address significant population-level health problems.
Manufacturing Scale-Up and Sustainability Efforts
Lilly is actively investing in its manufacturing capabilities, having opened its first dedicated genetic medicine manufacturing facility in Lebanon, Indiana, and produced the first commercial batch at its new Limerick, Ireland site. The company also exceeded its sustainability goal of reaching 1 billion people in resource-limited settings by 2030, reaching approximately 40 million people in 2025, and is developing new commitments for diabetes and obesity in these regions.
Strategic Business Development
Business development remains a critical component of Lilly's R&D strategy, with increased activity and average deal size in the first half of 2026. The focus is on acquiring potential new medicines in established and emerging therapeutic areas, particularly those addressing significant unmet needs and leveraging Lilly's development, regulatory, and manufacturing scale. The company aims to remain active in M&A while maintaining discipline to create long-term value.